As demand for AstraZeneca’s Covid-19 vaccine ebbs, the company is betting on tackling breast cancer and a different respiratory virus to drive growth
The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan TrefesAstraZeneca PLC produced one of the world’s most widely used Covid-19 vaccines. As, the company is betting on tackling breast cancer and a different respiratory virus.
After the pandemic hit, the drugmaker poured resources into fighting Covid-19. It produced a vaccine and a drug,
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca's COVID vaccine suffers a setback in nasal spray trialAttempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.
Read more »
COVID-19 nasal spray fails in trial by Oxford University and AstraZenecaThe drive to develop a nasal spray against COVID-19 infection suffered a setback Tuesday after AstraZeneca and Oxford University said a trial produced disappointing results.
Read more »
Healthcare professionals urge New Yorkers to get their annual breast cancer screenings | amNewYorkWith the COVID-19 pandemic easing, health care professionals are using Breast Cancer Awareness Month in October to remind women and those with prior histories of breast cancer in their families to schedule regular check-ups.
Read more »
300,000 COVID deaths among seniors avoided because of vaccines, report findsThere were 300,000 fewer COVID deaths and 650,000 fewer hospitalizations among seniors because of vaccines, according to a new HHS report.
Read more »